Julien Godet

Prof. Dr. Julien Godet

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2016 in Nature Communications
Verified
Journal Article
Open access
MBMarie N. Bongiovanni
Marie N. Bongiovanni
JGJulien Godet
Julien Godet
MHMathew Horrocks
Mathew Horrocks
LTLaura Tosatto
Laura Tosatto
ACAlexander R. Carr
Alexander R. Carr
SLSteven F. Lee
Steven F. Lee
Super-resolution microscopy allows biological systems to be studied at the nanoscale, but has been restricted to providing only positional information. Here, we show that it is possible to perform multi-dimensional super-resolution imaging to determine both the position and the environmental properties of single-molecule fluorescent emitters. The method presented here exploits the solvatochromic and fluorogenic properties of nile red to extract both the emission spectrum and the position of each dye molecule simultaneously enabling mapping of the hydrophobicity of biological structures. We validated this by studying synthetic lipid vesicles of known composition. We then applied both to super-resolve the hydrophobicity of amyloid aggregates implicated in neurodegenerative diseases, and the hydrophobic changes in mammalian cell membranes. Our technique is easily implemented by inserting a transmission diffraction grating into the optical path of a localization-based super-resolution microscope, enabling all the information to be extracted simultaneously from a single image plane.

10 April 2011 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
NRNatacha Rochel
Natacha Rochel
FCFabrice Ciesielski
Fabrice Ciesielski
JGJulien Godet
Julien Godet
EMEdelmiro Moman
Edelmiro Moman
MRManfred Rössle
Manfred Rössle
DMDino Moras
Dino Moras

13 July 2011 in Journal of Molecular Biology
Verified
Journal Article
Closed access
JDJean-Luc Darlix
Jean-Luc Darlix
JGJulien Godet
Julien Godet
RIRoland Ivanyi-Nagy
Roland Ivanyi-Nagy
PFPhilippe Fossé
Philippe Fossé
OMOlivier Mauffret
Olivier Mauffret
YMYves Mély
Yves Mély

15 July 2012 in Cancer Research
Verified
Journal Article
Closed access
PDF file
HJHana Janouskova
Hana Janouskova
AMAnne Maglott
Anne Maglott
DLDavid Y. Leger
David Y. Leger
CBCatherine Bossert
Catherine Bossert
FNFanny Noulet
Fanny Noulet
MDMonique Dontenwill
Monique Dontenwill
Integrins play a role in the resistance of advanced cancers to radiotherapy and chemotherapy. In this study, we show that high expression of the α5 integrin subunit compromises temozolomide-induced tumor suppressor p53 activity in human glioblastoma cells. We found that depletion of the α5 integrin subunit increased p53 activity and temozolomide sensitivity. However, when cells were treated with the p53 activator nutlin-3a, the protective effect of α5 integrin on p53 activation and cell survival was lost. In a functional p53 background, nutlin-3a downregulated the α5 integrin subunit, thereby increasing the cytotoxic effect of temozolomide. Clinically, α5β1 integrin expression was associated with a more aggressive phenotype in brain tumors, and high α5 integrin gene expression was associated with decreased survival of patients with high-grade glioma. Taken together, our findings indicate that negative cross-talk between α5β1 integrin and p53 supports glioma resistance to temozolomide, providing preclinical proof-of-concept that α5β1 integrin represents a therapeutic target for high-grade brain tumors. Direct activation of p53 may remain a therapeutic option in the subset of patients with high-grade gliomas that express both functional p53 and a high level of α5β1 integrin. Cancer Res; 72(14); 3463–70. ©2012 AACR.

28 June 2018 in Allergy
Verified
Journal Article
Open access
PDF file
OVOlivier Vandenplas
Olivier Vandenplas
JGJulien Godet
Julien Godet
LHLaura Hurdubaea
Laura Hurdubaea
CRCatherine Rifflart
Catherine Rifflart
HSHille Suojalehto
Hille Suojalehto
EIEuropean network for the PHenotyping of OCcupational ASthma (E‐PHOCAS) investigators
European network for the PHenotyping of OCcupational ASthma (E‐PHOCAS) investigators
Background: High‐molecular‐weight (HMW) proteins and low‐molecular‐weight (LMW) chemicals can cause occupational asthma (OA) although few studies have thoroughly compared the clinical, physiological, and inflammatory patterns associated with these different types of agents. The aim of this study was to determine whether OA induced by HMW and LMW agents shows distinct phenotypic profiles.Methods: Clinical and functional characteristics, and markers of airway inflammation were analyzed in an international, multicenter, retrospective cohort of subjects with OA ascertained by a positive inhalation challenge response to HMW (n = 544) and LMW (n = 635) agents.Results: Multivariate logistic regression analysis showed significant associations between OA caused by HMW agents and work‐related rhinitis (OR [95% CI]: 4.79 [3.28‐7.12]), conjunctivitis (2.13 [1.52‐2.98]), atopy (1.49 [1.09‐2.05]), and early asthmatic reactions (2.86 [1.98‐4.16]). By contrast, OA due to LMW agents was associated with chest tightness at work (2.22 [1.59‐3.03]), daily sputum (1.69 [1.19‐2.38]), and late asthmatic reactions (1.52 [1.09‐2.08]). Furthermore, OA caused by HMW agents showed a higher risk of airflow limitation (1.76 [1.07‐2.91]), whereas OA due to LMW agents exhibited a higher risk of severe exacerbations (1.32 [1.01‐1.69]). There were no differences between the two types of agents in the baseline sputum inflammatory profiles, but OA caused by HMW agents showed higher baseline blood eosinophilia and a greater postchallenge increase in fractional nitric oxide.Conclusion: This large cohort study describes distinct phenotypic profiles in OA caused by HMW and LMW agents. There is a need to further explore differences in underlying pathophysiological pathways and outcome after environmental interventions.

1 September 2016 in Orthopaedics & Traumatology: Surgery & Research
Verified
Journal Article
Closed access
LCL. Cherchi
L. Cherchi
JCJ.F. Ciornohac
J.F. Ciornohac
JGJulien Godet
Julien Godet
PCP. Clavert
P. Clavert
JKJ.-F. Kempf
J.-F. Kempf